Delving into the Latest Updates on FCN-098 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

NTRK

Mechanism

NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Chongqing Fuchuang Pharmaceuticals Research Co., Ltd.

Active Organization

Fochon Pharmaceuticals Ltd.

Inactive Organization

Chongqing Fuchuang Pharmaceuticals Research Co., Ltd.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1. Observe the safety and tolerability of single oral and continuous oral administration of FCN-098 in the treatment of patients with advanced solid tumors that cannot be surgically removed; 2. Determine the maximum tolerated dose (MTD) and recommended dose (RP2D) of Phase II clinical study and dose-limiting toxicity (DLT) of FCN-098.

Start Date07 Jan 2022

Sponsor / Collaborator

Chongqing Fuchuang Pharmaceuticals Research Co., Ltd.

NCT05212987 / RecruitingPhase 1

A Multi-center, Open, Single-arm Phase I Dose Exploratory Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Primary Antitumor Activity of FCN-098 in Patients With Advanced Solid Tumors

A multi-center, open, single-arm phase I dose exploratory study to evaluate the safety, tolerability, pharmacokinetic characteristics and primary antitumor activity of FCN-098 in patients with advanced solid tumors.

Start Date31 Dec 2021

Sponsor / Collaborator

Fochon Pharmaceuticals Ltd.

100 Clinical Results associated with FCN-098

Login to view more data

100 Translational Medicine associated with FCN-098

Login to view more data

100 Patents (Medical) associated with FCN-098

Login to view more data

100 Deals associated with FCN-098

Login to view more data